The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of vemurafenib (V), a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
Brian Higgins
Employment or Leadership Position - Roche/Genentech
Kenneth Daniel Kolinsky
Employment or Leadership Position - Roche/Genentech
Kathleen Schostack
Employment or Leadership Position - Roche/Genentech
Gideon Bollag
Employment or Leadership Position - Plexxikon
Richard J. Lee
Employment or Leadership Position - Roche/Genentech
Fei Su
Employment or Leadership Position - Roche/Genentech
Kathryn Packman
Employment or Leadership Position - Roche/Genentech